K. Eckhardt

Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.

K. Nackaerts, O. Riesterer, R. Stahel, 2015, The Lancet. Oncology.

Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial

T. Pabst, E. Zucca, N. Fischer, 2013, Annals of Hematology.

Cancer Therapy : Clinical Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermato fi brosarcoma Protuberans : AMulticenter Phase II DeCOG Trial with Long-term Follow-up

J. Utikal, A. Hauschild, D. Schadendorf, 2014 .

Rituximab, bendamustine and lenalidomide in patients with aggressive B‐cell lymphoma not eligible for anthracycline‐based therapy or intensive salvage chemotherapy – SAKK 38/08

S. Rondeau, T. Pabst, E. Zucca, 2016, British journal of haematology.